Spelling suggestions: "subject:"bowel"" "subject:"vowel""
541 |
Inflammatory bowel disease geneticsCotterill, Lynn January 2011 (has links)
Inflammatory bowel disease (IBD), which includes the subtypes Crohn's disease (CD) and ulcerative colitis (UC), is a common disease particularly in the Western world. IBD is characterised by inflammation of the small intestine and/or colon. The two subtypes affect different gut locations but both show an increased intestinal permeability or the 'leaky gut syndrome'. This led to the hypothesis that tight junction (TJ) proteins expressed in the epithelium may affect the intestinal permeability as a cause or effect of IBD.Initially, variants in the CARD15, IL23R and ATG16L1 genes, previously associated with an increased risk of IBD, were genotyped in a cohort of 500 IBD (295 CD and 205 UC) patients and 877 matched controls. These variants were significantly associated in our cohort. A random effects meta-analysis was undertaken on all previously reported CD associations with the variant rs2241880 from ATG16L1 (n=25, p=0.0017, OR: 1.36 95% CI 1.12-1.66) and with rs11209026 from IL23R (n=26, p=0.0006, OR: 0.37 95% CI 0.21-0.67), showing pooled odds ratios consistent with those reported in our cohort. Individuals carrying >1 CARD15 mutant variant were found to have a 2.5 fold increased risk of CD (p=0.0001). Candidate TJ proteins were chosen on the basis of previous reported associations and through the investigation of the claudin proteins which are abundant at TJs. Twenty one candidate genes were selected and 79 variants successfully genotyped in up to 1063 IBD (502 CD and 478 UC) and 870 control patients. Significant associations were detected with variants in the CLDN1, CLDN5 and CDH1 genes with CD; CLDN5, CLDN8 and CDH1 variants were associated to IBD; and the rs7791132 variant (between CLDN4 and ELN) and a CDH1 variant were associated to UC. The CLDN1 rs6809685 variant trended towards association in a Toronto ascertained IBD replication cohort (genotypic p=0.04, allelic p=0.06) suggesting this may be a novel IBD susceptibility variant. Small intestinal biopsies from CD patients with known rs6809685 genotypes showed a dose dependent reduced immunohistochemical staining of claudin 1 with carriage of the mutant G allele. Claudin 1 helps seal TJs and reduced levels may increase risk of CD.Peroxisome proliferator activator receptors (PPARs) can directly affect TJ proteins and could therefore affect intestinal permeability. Twelve PPARγ variants were genotyped in up to 1050 IBD (502 CD and 467 UC) and 725 control patients. Significant genotypic associations were found with the rs2067819 variant in CD (p=0.05) and IBD (p=0.02), and also the rs13099634 variant in UC (P=0.02). There was a strong gender difference particularly for rs2067819 and rs4135247, where allelic associations were highly significant and increased risk of IBD in men (p=0.01 and p=0.007 respectively). However no significant associations were found in the female cohort. Troglitazone a PPARα agonist increased Caco2 cell transepithelial electrical resistance (TEER), a marker of TJ integrity, and increased expression of claudins -3 and -4. In contrast, the PPARα antagonist GW6471 reduced the TEER without causing cell death and PPARγ ligands did not affect TEER measurements. In summary, using a robust cohort of cases and controls the data indicates that variants in genes encoding TJ proteins may affect susceptibility to IBD and that PPARs can regulate these proteins altering intestinal permeability.
|
542 |
Análise de polimorfismos dos genes de enzimas de metabolização de detoxificação em doenças inflamatórias crônicasRech, Tássia Flores January 2013 (has links)
A doença inflamatória intestinal (DII) e a esclerose sistêmica (ES) são doenças inflamatórias crônicas de difícil diagnóstico e tratamento. A etiologia da DII e da ES ainda não é completamente compreendida, mas sabe-se que fatores genéticos, imunológicos e ambientais estão envolvidos na sua patogênese. A DII possui dois principais subtipos clínicos: a doença de Crohn (DC) e a retocolite ulcerativa (RCU), caracterizados pela inflamação do intestino delgado e/ou cólon. Evidências sugerem que o aumento do estresse oxidativo desempenha um papel importante na fisiopatologia da DII. A ES é uma doença inflamatória autoimune rara, caracterizada pela fibrose progressiva da pele e de órgãos internos. A hipótese de que o aumento do dano oxidativo pode iniciar o dano vascular e desencadear os eventos patológicos observados na ES vem sendo investigada. Genes e enzimas envolvidos na metabolização (Fase I) e detoxificação (Fase II) de xenobióticos são utilizados como marcadores de susceptibilidade para o desenvolvimento de doenças que possuem fatores ambientais como fatores de risco. Em uma reação de Fase I, as enzimas do Citocromo P450 (CYP) inserem um átomo de oxigênio em um substrato deixando-o eletrofílico e reativo, criando um sítio para posterior conjugação pelas enzimas de Fase II. As enzimas Glutationa S-tranferases (GST) de Fase II catalisam a conjugação da glutationa com uma grande variedade de compostos eletrofílicos, detoxificando substâncias endógenas e exógenas. A atividade catalítica aumentada das enzimas CYP, bem como a falha na detoxificação de metabólitos pelas GST pode contribuir para o aumento do estresse oxidativo. O objetivo deste estudo foi investigar o papel de polimorfismos nos genes que codificam enzimas de metabolização (CYP1A*2C e CYP2E1*5B) e detoxificação (GSTT1 nulo, GSTM1 nulo e GSTP1 Ile105Val) na susceptibilidade a estas doenças. O grupo de pacientes com DII era constituído por 235 indivíduos e o grupo controle por 241 indivíduos, todos eurodescendentes. Na ES, 122 pacientes (99 eurodescendentes e 23 afrodescendentes) e 329 controles (241 eurodescendentes e 87 afrodescendentes) foram analisados. Os polimorfismos CYP foram genotipados por PCR-RFLP, enquanto que os polimorfismos em GSTT1 e GSTM1 foram genotipados por PCR multiplex e PCR-RFLP para GSTP1. As frequências alélicas e genotípicas foram comparadas entre pacientes e controles usando o teste de Qui-Quadrado. A respeito dos resultados das análises em DII, as frequências alélicas e genotípicas dos polimorfismos CYP1A1*2C, CYP2E1*5B e GSTP1 Ile105Val, bem como as frequências genotípicas do polimorfismo de presença/ausência de GSTM1, foram similares nos três grupos de pacientes (DII, DC e RCU) quando comparados ao grupo controle (P>0,05). Observouse uma frequência significativamente aumentada do genótipo nulo de GSTT1 no grupo de pacientes com DII quando comparado ao grupo controle [0,28 vs 0,18; χ² com Yates P=0,02; OR=1,71 (IC 95% 1,09 –2,71)]. Quando separamos o grupo de pacientes em DC ou RCU, esta frequência permaneceu significativamente aumentada somente no grupo de pacientes com RCU comparado ao grupo controle [0,29 vs 0,18; χ² com Yates P=0,035; OR=1,84 (IC 95% 1,03 –3,24)]. Com relação aos resultados das análises na ES, uma frequência significativamente aumentada do genótipo *1A/*1A (P=0,03; 0,74 vs. 0,61) e do alelo *1A (P=0,013; 0,86 vs 0,78; OR=0,57, IC 95% 0,36–0,90) do polimorfismo CYP1A1*2C foi observada entre os indivíduos controles eurodescendentes. Em contrapartida, a frequência do alelo *2C estava significativamente aumentada entre os pacientes de mesma etnia (P=0,013; 0,22 vs 0,14; OR=1,75, IC 95% 1,11–2,74). Com relação às frequências alélicas e genotípicas dos polimorfismos CYP2E1*5B e GSTP1 Ile105Val, e as frequências genotípicas do polimorfismo de presença/ausência de GSTM1, nenhuma diferença significativa foi observada quando os grupos de pacientes de ambas as etnias foram comparados aos grupos controle (P>0,05). Uma frequência significativamente aumentada do genótipo nulo de GSTT1 [0,29 vs 0,18; χ² com Yates P=0,035; OR=1,85 (IC 95% 1,03–3,29)], bem como uma alta frequência da dupla deleção de GSTT1/GSTM1 [0,19 vs 0,08; χ² com Yates P=0,007; OR=2,62 (IC 95% 1,25 –5,46)], foi observada no grupo de pacientes comparado aos controles (eurodescendentes). Estas associações não se repetiram entre indivíduos afrodescendentes. Concluindo, nossos resultados sugerem que o genótipo nulo de GSTT1 está associado à susceptibilidade a DII e pode influenciar na definição do curso da doença para a RCU. Além disso, o genótipo nulo de GSTT1 sozinho ou em combinação com o genótipo nulo de GSTM1 é um fator genético de susceptibilidade para a ES, enquanto que o genótipo *1A/*1A ou a presença do alelo *1A do polimorfismo CYP1A1*2C pode exercer um papel protetor contra o desenvolvimento da ES em indivíduos eurodescendentes. / Inflammatory bowel disease (IBD) and systemic sclerosis (SSc) are chronic inflammatory diseases of difficult diagnosis and treatment. The etiology of IBD and SSc is not completely understood but it is known that genetic, immunologic and environmental factors are involved in its pathogenesis. Crohn’s disease (CD) and ulcerative colitis (UC) are the two major subtypes of IBD, characterized by inflammation of the small intestine and/or colon. Evidences suggest that the increase of oxidative stress plays an important role in the pathophysiology of IBD. SSc is a rare autoimmune inflammatory disease of the connective tissue characterized by progressive fibrosis of the skin and internal organs. The hypothesis that the increase of oxidative stress can initiate vascular damage and triggers the pathological events in SSc has been investigated. Genes and enzymes involved in metabolism (Phase I) and detoxification (Phase II) of xenobiotics are used as markers of susceptibility to the development of diseases that have environmental factors as risk factors. In a Phase I reactions, the Cytochrome P450 (CYP) enzymes insert an oxygen atom in a substrate that making it more electrophilic and reactive, and creating a site for subsequent conjugation by Phase II enzymes. Phase II Glutathione S-transferases (GSTs) enzymes catalyze the conjugation of glutathione with a variety of electrophilic compounds, detoxifying endogenous and exogenous substances. A higher catalytic activity of CYP enzymes, as well as the failure in detoxifying of metabolites by GST enzymes may to contribute for the increase of oxidative stress. The aim of this study was investigated the role of polymorphisms in genes coding Phase I enzymes (CYP1A*2C and CYP2E1*5B) and Phase II (GSTT1 null, GSTM1 null and GSTP1 Ile105Val) in susceptibility to these diseases. IBD group was constituted by 235 patients and the control group by 241 individuals, all European-derived. In SSc group, 122 patients (99 European-derived and 23 African-derived) and 329 controls (241 European-derived and 87 African-derived) were analyzed. The CYP polymorphisms were genotyped by PCR-RFLP, whereas polymorphisms in GSTM1 and GSTT1 were genotyped by multiplex PCR and PCRRFLP for GSTP1. Allelic and genotypic frequencies were compared between patients and controls using the Chi-square test. Concerning IBD, allelic and genotypic frequencies of CYP1A1*2C, CYP2E1*5B and GSTP1 Ile105Val polymorphisms, as well as genotypic frequencies of GSTM1 presence/absence polymorphism were similar in all groups patients (IBD, CD, and UC) and controls (P>0.05). We observed a significantly increased frequency of GSTT1 null genotype in IBD group as compared to controls [0.28 vs. 0.18, χ ² with Yates P=0.02, OR=1.71 (95% CI 1.09 – 2.71)]. When patients were classified in CD or UC group, this frequency remained significantly increased only among UC patients [0.29 vs. 0.18, χ ² with Yates P=0,035, OR=1.84 (95% CI 1.03 – 3.24)] as compared to controls. Regarding results in SSc, a frequency significantly increased of *1A/*1A genotype (P=0.03; 0.74 vs. 0.61) and *1A allele (P=0.013; 0.86 vs 0.78; OR=0.57, 95% CI 0.36–0.90) from CYP1A1*2C polymorphism was observed among European-derived controls. On the other hand, the frequency of *2C allele was significantly increased among patients of same ethnic group (P=0.013; 0.22 vs 0.14; OR=1.75, 95% CI 1.11–2.74). The allelic and genotypic frequencies of CYP2E1*5B and GSTP1 Ile105Val polymorphisms, as well as genotypic frequencies of GSTM1 presence/absence polymorphism were similar between SSc patients and controls of both ethnic groups (P>0.05). We observed a significantly increased frequency of GSTT1 null genotype [0.29 vs. 0.18, χ ² with Yates P=0.035, OR=1.85 (95% CI 1.03–3.29)], as well as an increased frequency of GSTT1/GSTM1 double-null in SSc patients as compared to controls [0.19 vs. 0.08; χ ² with Yates P=0.007, OR=2.62 (95% CI 1.25 – 5.46)]. These associations were exclusive to European-derived individuals. In conclusion, our results suggest that the GSTT1 null genotype is associated with susceptibility to IBD and may influence in defining the course of the disease for RCU. Furthermore, the GSTT1 null genotype alone or combined with GSTM1 null genotype is a susceptibility genetic factor to SSc, while the *1A/*1A genotype or the presence of *1A allele from CYP1A1*2C polymorphism may plays a protector role in SSc development in Brazilian Europeanderived individuals.
|
543 |
Potencial terapêutico da saliva de Aedes aegypti na inflamação intestinal experimental / Therapeutic activity of Aedes aegypti saliva in experimental colitisHelioswilton Sales de Campos 17 December 2015 (has links)
As Doenças Inflamatórias Intestinais (DII) são caracterizadas por resposta inflamatória exacerbada na mucosa intestinal, com desbalanço entre mecanismos pró-inflamatórios e reguladores. Entretanto, até o momento, nenhuma terapia é curativa e vários pacientes são refratários ou intolerantes a elas, necessitando de intervenções cirúrgicas para combater as complicações da doença. Sendo assim, é evidente que novas terapias são necessárias para o controle da progressão das DII. Dessa forma, como a saliva de insetos hematófagos constitui uma fonte importante de moléculas com potencial farmacológico, o objetivo desse trabalho foi avaliar a atividade terapêutica do extrato de glândula salivar (EGS) do Aedes aegypti e suas frações na colite experimental. Para tal, camundongos C57BL/6 foram submetidos à indução de colite pela administração de água contendo 3% de dextran sulfato de sódio (DSS). Os resultados demonstraram melhora na condição clínica e no escore pós-morte dos camundongos tratados com o EGS i.v. ou i.p. Essa melhora foi acompanhada de redução de leucócitos no sangue periférico, principalmente quando os animais foram tratados i.v. Além disso, redução do infiltrado inflamatório e das citocinas patogênicas IL-12, IFN-?, TNF-?, IL- 1? e IL-5, no intestino, foi também associada ao tratamento. Ademais, houve diminuição da frequência de linfócitos TCD4+ produtores de IFN-?, IL-17 e IL-4 no baço e nos linfonodos mesentéricos (LNM) dos animais tratados com EGS. Ainda, uma menor frequência de células CD11b+ no baço e CD49b+ nos LNM também foi detectada nos animais com inflamação intestinal tratados com o EGS. De forma interessante, quando expostos por dois ciclos ao DSS, o tratamento precoce com EGS (1o ciclo) protegeu os camundongos do desenvolvimento da colite após nova indução da inflamação intestinal (2o ciclo), sugerindo que a saliva do A. aegypti possui componentes com capacidade de retardar o aparecimento e a gravidade da recidiva da doença. A melhora na condição clínica associada ao tratamento com EGS parece também estar associada à modulação de populações bacterianas no intestino com características supostamente colitogênicas (Pseudomonas monteilii) e protetoras (Ruminococus champanelensis e Turicibacter sanguinis). De fato, o transplante de microbiota de camundongos tratados com EGS para animais que sofreram indução da colite levou à aparente melhora do escore pós-morte e à redução de leucócitos circulantes. Além disso, o transplante diminuiu a expressão de RNAm das citocinas inflamatórias IFN-? e IL-1?, indicando que alterações na microbiota intestinal podem ser um dos mecanismos pelos quais o EGS modula a colite experimental. Finalmente, experimentos utilizando a cromatografia líquida de alta performance (HPLC) sugerem que uma fração (F3) do extrato bruto da saliva, pode ser a responsável pela melhora observada nos sinais clínicos da doença. De forma geral, o EGS e seus componentes parecem representar uma fonte importante de moléculas imunomoduladoras com potencial terapêutico no tratamento da inflamação intestinal induzida experimentalmente / Inflammatory Bowel Disease (IBD) is an inflammatory disorder characterized by an imbalance between inflammatory and regulatory immune responses at the gut mucosa. However, current therapies are not totally effective and a plenty of patients require repeated surgeries to control disease complications. So, it is clear that novel therapies are still needed to control IBD progression. Thereby, since saliva from bloodsucking arthropods is a rich source of pharmacologically bioactive molecules, the aim of this study was to evaluate the therapeutic activity of Aedes aegypti total (SGE) and fractionated saliva in the treatment of experimental colitis. For this purpose, C57BL/6 male mice were exposed to 3% dextran sulfate sodium (DSS) in drinking water. The results showed an improvement in clinical disease outcome and postmortem scores after SGE treatment, regardless the route of administration used (i.p. or i.v.). This amelioration was accompanied by the systemic reduction in peripheral blood lymphocytes, especially when the i.v route was used. Furthermore, a reduction in the inflammatory area together with a local diminishment of IFN- ?, TNF-?, IL-1? and IL-5 cytokines were observed in the colon of SGE-treated mice. Similarly, a reduction of the frequency of TCD4+ lymphocytes producing IFN-?, IL-17 and IL-4 was observed in spleen and mesenteric lymph nodes (MLN) of SGE-treated mice. A lower frequency of CD11b+ cells in spleen and CD49b+ in MLN was also observed after SGE treatment. Interestingly, early treatment with SGE led to mice protection from a late DSS rechallenging, indicating that the mosquito saliva may present components able to prevent disease relapse. Clinical improvement due to SGE therapy seems to be also related to the modulation of intestinal bacterial population with different characteristics. Thus, SGE-therapy managed to a diminishment of colitogenic (Pseudomonas monteilii) and improvement of protective (Ruminococus champanelensis e Turicibacter sanguinis) bacteria. In fact, microbiota transplantation from SGE-tretaed mice to mice exposed to DSS-colitis improved postmortem scores and induced systemic diminishment in peripheral blood lymphocytes. Additionally, a reduced mRNA levels for the inflammatory cytokines IFN-? and IL-1?, was observed in transplanted mice, pointing to the effects of SGE-therapy in the modulation of gut microbes as one of the mechanisms related to the improvement of disease outcome. Finally, high performance liquid chromatography (HPLC) experiments suggested a major SGE pool fraction (F3) able to ameliorate disease signs. In conclusion, SGE and its components might represent a source of important immunomodulatory molecules with promising therapeutic activity for experimentally induced intestinal inflammation.
|
544 |
Anemia nas doenças inflamatórias intestinais: prevalência e fatores de riscoAntunes, Carla Valéria de Alvarenga 10 July 2014 (has links)
Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-01-21T16:51:59Z
No. of bitstreams: 1
carlavaleriadealvarengaantunes.pdf: 1487917 bytes, checksum: c0d630797135f7fb32b18c3ae9000d7c (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-01-25T18:46:52Z (GMT) No. of bitstreams: 1
carlavaleriadealvarengaantunes.pdf: 1487917 bytes, checksum: c0d630797135f7fb32b18c3ae9000d7c (MD5) / Made available in DSpace on 2016-01-25T18:46:52Z (GMT). No. of bitstreams: 1
carlavaleriadealvarengaantunes.pdf: 1487917 bytes, checksum: c0d630797135f7fb32b18c3ae9000d7c (MD5)
Previous issue date: 2014-07-10 / FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais / Anemia de difícil tratamento é uma manifestação clínica comumente observada nos
pacientes portadores de doenças inflamatórias intestinais, sendo responsável por
prejuízo significativo na qualidade de vida destes pacientes. O objetivo deste estudo
foi avaliar, nos pacientes com doença inflamatória intestinal, a prevalência e os
fatores de risco da anemia suas possíveis etiologias. Neste estudo de corte
prospectivo observacional foram recrutados: 100 pacientes portadores de Doença de
Crohn e 100 pacientes portadores de Retocolite ulcerativa, diagnosticados e
acompanhados regularmente no Centro de Doenças Inflamatórias Intestinais do
Hospital Universitário da Universidade Federal de Juiz de Fora, para avaliação
hematológica, bioquímica e imunológica. Foram obtidas amostras de sangue (20 ml)
e realizados os seguintes exames em todos os pacientes: hemograma completo,
VGM, HGM, CHGM, plaquetas, ácido fólico, vitamina B12, reticulócitos, índice de
saturação da transferrina, ferritina, ferro sérico, PCR e VHS. Foram adotados para
o diagnóstico de anemia os mesmos critérios da WHO (World Health Organization).
Foi considerado Anemia por Deficiência de Ferro quando houve diminuição dos
níveis séricos de ferro (< 37 μg/dl para mulheres e < de 59 μg/dl para homens), da
ferritina (<30μg/l- na ausência de dados clínicos, laboratoriais ou endoscópicos de
inflamação intestinal e < 100 μg/l - na presença de quaisquer destes dados), do
índice de saturação da transferrina (<16%). Foi considerado Anemia da Doença
Crônica quando houve diminuição dos níveis séricos de ferro (< 37 μg/dl para
mulheres e < de 59 μg/dl para homens), aumento da ferritina (>100μg/l) e diminuição
do índice de saturação da transferrina (<16%). - na presença de dados clínicos,
laboratoriais ou endoscópicos de inflamação intestinal e Anemia Mista quando houve
diminuição dos níveis séricos de ferro (< 37 μg/dl para mulheres e < de 59 μg/dl para
homens) e ferritina entre 30 e 100μg/l. As anemias foram classificadas em
hiporregenerativas quando a contagem absoluta de reticulócitos estava abaixo de
50000 e normoproliferativas ou normorregenerativas quando a contagem absoluta
de reticulócitos estava acima de 100000/mm³. / Anemia difficult to treat is a clinical manifestation commonly seen in patients with
inflammatory bowel disease , being responsible for significant impairment in quality of
life of these patients. The aim of this study was to evaluate, in patients with
inflammatory bowel disease, the prevalence and factors risk of anemia and possible
etiologies of anemia in their possible occurrence. In this cross-sectional study of adult
patients with inflammatory bowel disease (IBD) were recruited, of which: 100 patients
with Crohn's disease and 100 patients with ulcerative colitis, diagnosed and regularly
followed at the Center for Inflammatory Bowel Diseases , University Hospital, Federal
University of Juiz de Fora , for haematological, biochemical and immunological
evaluation. Blood samples ( 20 ml ) were obtained and the following examinations
were performed in all patients: CBC, MCV, MCH , CHCM , platelets , folic acid,
vitamin B12 , reticulocytes , transferrin saturation index , ferritin , serum iron, CRP
and ESR . For the diagnosis of anemia the same criteria of WHO (World Health
Organization) were adopted . Was considered Iron Deficiency Anemia when there
was a decrease in serum iron levels ( < 37 mg / dl for women and < 59 g / dl for men
) , ferritin (< 30μg/l - in the absence of clinical, laboratory data or endoscopic
intestinal inflammation and <100 mg / l - in the presence of any of these data) , the
ratio of transferrin saturation (<16 %). Anemia was considered the Crohnic Disease
Anemia when there was a decrease in serum iron levels (< 37 mg / dl for women and
< 59 g / dl for men), elevated ferritin ( > 100μg / l ) and decreased transferrin
saturation index (<16 %). - in the presence of clinical, laboratory and endoscopic data
of intestinal inflammation and Mix Anemia when there was a decrease in serum iron
levels ( < 37 mg / dl for women and < 59 g / dl for men) and ferritin between 30 and
100μg / l . Anemia were classified into hiporregenerative when absolute reticulocyte
count was below 50,000 and normoproliferative or normorregenerative when the
absolute reticulocyte count was above 100,000.
|
545 |
Risque d'accident artériel aigu chez les patients atteints de maladie inflammatoire chronique intestinale et impact des traitements sur le risque : analyse des bases de données médico administratives françaises PMSI et SNIIRAM / Risk of ischemic heart disease, cerebrovascular disease and peripheral artery disease in patients with inflammatory bowel disease and impact of medical treatment on these risks : analysis of the French administrative health databases PMSI and SNIIRAMKirchgesner, Julien 13 December 2017 (has links)
Le risque d’accidents artériels aigus chez les patients atteints de maladie inflammatoire chronique intestinale (MICI) reste incertain. L’objectif de cette thèse est d’évaluer le risque d’accident artériel aigu chez les patients atteints de MICI et l’impact des traitements sur le risque à partir des bases de données médico administratives françaises PMSI et SNIIRAM. La prise en charge thérapeutique des patients atteints de MICI a été initialement étudiée afin de valider le code diagnostique dans les bases de données. L’exposition au traitement, les taux d’hospitalisation et de chirurgie sont similaires à ceux attendus et les taux d’incidence sont comparables à ceux rapportés dans d’autres populations. Les patients atteints de maladie de Crohn (MC) et rectocolite hémorragique (RCH) ont un surrisque d’accident artériel aigu comparé à la population générale. Le risque le plus élevé est observé chez les patients de moins de 55 ans. L’activité de la MICI est un facteur de risque indépendant d’accident artériel aigu, avec une magnitude d’effet similaire dans la MC et la RCH. Comparés aux patients non exposés, les patients exposés à la monothérapie thiopurines, anti-TNFs et combothérapie ont un risque moins élevé d’accident artériel aigu, mais cette différence est seulement significative chez les patients exposés à la combothérapie. La diminution du risque est la plus importante chez les hommes atteints de MC exposés à la combothérapie. La modulation du risque d’accident artériel aigu devrait être prise en compte dans la balance bénéfice-risque des traitements par thiopurines et anti-TNFs chez les patients atteints de MICI. / The risk of acute arterial events in inflammatory bowel disease (IBD) remains unclear. The objectives of this thesis are to assemble a nationwide cohort of IBD patients based on the French administrative health databases, in order to assess the risk of acute arterial events in IBD and the impact of immunosuppressive treatment on the risk. Disease course and therapeutic management of IBD were first studied, in order to validate the coding diagnosis of IBD in the databases. Treatment exposure, hospitalisation, and surgery rates are similar to current standard of care and incidence rates are in the range of those reported in other populations. Patients with Crohn’s disease (CD) and ulcerative colitis (UC) have an increased risk of acute arterial events compared with the general population. The highest risk is observed in patients under the age of 55 years. Disease activity is an independent risk factor of acute arterial events, with a similar magnitude of risk in CD and UC. Exposure to thiopurine and anti-TNF monotherapies, and combination therapy are all numerically associated with a decreased risk of acute arterial events compared to unexposed patients, although the difference is only statistically significant for patients exposed to combination therapy. The magnitude in risk reduction is highest in men with CD exposed to combination therapy. These studies support the concept that a tight control of inflammation is crucial in patients with IBD to avoid IBD-related systemic complications. Prevention of acute arterial events should be considered in the benefit-risk balance assessment of thiopurines and anti-TNFs treatment in IBD patients, according to age, sex and IBD subtype.
|
546 |
Lactobacillus plantarum i kombination med andra bakteriestammar vid diarré predominant IBS : Effekt att lindra symtomen buksmärta vid IBS-D?Musa, Matilda January 2020 (has links)
Bakgrund: IBS (Irritable bowel syndrome) är en funktionell mag-tarmsjukdom med en oklar orsak och patofysiologi. IBS förekommer mest hos kvinnor och karakteriseras av buksmärta, uppblåsthet, diarré och/eller förstoppning samt ökad gasbildning. I nuläget finns inga läkemedel som botar sjukdomstillståndet, och den senaste tiden har intresset för probiotika som behandling av IBS ökat. Probiotika innehåller levande mikroorganismer som anses ha en gynnsam effekt på tarmflorans sammansättning, samt kan tros ha en symtomatisk effekt vid IBS. Syfte: Syftet med detta litteraturarbete är att ta reda på om kosttillskott som innehåller bakteriearten Lactobacillus plantarum har en positiv effekt för att lindra symtomen hos patienter som lider av en diarrépredominant IBS. Metod: Sex randomiserade, dubbelblinda och placebo-kontrollerade studier granskades. Studierna utvärderade effekten av den enskilda bakteriearten L. plantarum eller en kombination av probiotika som innehöll L. plantarum för symtomlindring hos IBS-patienter. Artikelsökning utfördes i databasen PubMed via Linnéuniversitetets bibliotek. Resultat: Tre av de fyra studierna som undersökte L. plantarum i kombination med andra bakteriestammar påvisade en statistiskt signifikant förbättring av symtomen buksmärta hos IBSpatienter. En av de två studierna som undersökte enbart L. plantarum visade en signifikant förbättring av symtomen buksmärta. Två av sex studier visade ingen signifikant förbättring av symtomlindring mellan probiotika- och placebo gruppen. Slutsats: Utifrån sammanställningen påvisades att effekten uppnåddes framförallt i gruppen med måttliga IBS besvär. Dock gav inte behandling med L. plantarum alltid en statistisk signifikant förbättring av symtomlindring hos diarré predominanta IBS-patienter. Vidare studier behövs på subtypen diarré predominant IBS för att stärka och fastställa L. plantarums effekt.
|
547 |
Régulation de la perméabilité intestinale au cours du syndrome de l'intestin irritable : role du système ubiquitine-protéasome et impact de l'obésité / Regulation of intestinal permeability during irritable bowel syndrome : role of proteasome and impact of obesityBahlouli, Wafa 23 September 2019 (has links)
Le syndrome de l’intestin irritable (SII) est un trouble fonctionnel d’origine multifactorielle, impliquant des facteurs environnementaux tels que le stress, l’alimentation et met en jeu un dysfonctionnement de l’axe intestin-cerveau, une micro-inflammation, une dysbiose et une hyperperméabilité intestinale. Le rôle du protéasome dans la régulation de la barrière intestinale au cours du SII a été étudié. De plus, ces troubles fonctionnels intestinaux (TFI) ont également été décrits comme exacerbés chez des patients souffrant d’obésité, dont la physiopathologie est complexe. Néanmoins, les mécanismes impliqués dans cette association restent mal compris et ont donc été recherchés. Dans ce travail, des modèles murins « SII-like » comme le modèle de stress « water avoidance stress » ou WAS et le modèle post-inflammatoire « post-TNBS » ont été utilisés afin d’étudier l’impact d’une inhibition du protéasome sur la régulation de la perméabilité intestinale. L’inhibition pharmacologique du protéasome par le PR-957 ou l’utilisation de souris invalidées pour une sous unité β2i du protéasome limite l’hyperperméabilité intestinale. Une supplémentation orale en glutamine permet également de diminuer la perméabilité intestinale. Une étude protéomique au niveau colique des souris WAS et une étude de l’ubiquitome colique de patients souffrant de SII à profil diarrhéique confirment l’implication du protéasome dans la physiopathologie du SII. Nous avons ensuite cherché à comprendre le lien entre l’obésité et le SII en combinant des modèles d’obésité (génétique et induite par une alimentation riche en graisses ou HFD) et le modèle WAS. Seules les souris HFD présentent une exacerbation de l’hyperperméabilité intestinale et une corticostéronémie plasmatique élevée en réponse au modèle WAS. Des études complémentaires suggèrent que ces résultats sont indépendants de la leptine, de la glycémie et du microbiote intestinal. Nos travaux proposent donc de nouvelles pistes de prise en charge des patients souffrant de SII, par intervention nutritionnelle via la glutamine ou en utilisant le protéasome comme cible thérapeutique. Nous suggérons également un rôle de l’alimentation (riche en graisse) dans le développement des TFI au cours de l’obésité. / Irritable bowel syndrome (IBS) is a multifactorial functional disorder, involving environmental factors (stress and diet for instance), gut-brain-axis dysfunction, micro-inflammation, dysbiosis and an alteration of intestinal permeability. The role of the proteasome in the regulation of the intestinal barrier during IBS has been studied. In addition, these intestinal functional disorders have also been described in patients with obesity. Nevertheless, the mechanisms underlying an association of intestinal functional disorders in the obesity context, remain poorly understood and have therefore been investigated in this thesis. In this study, "IBS-like" mouse models such as water avoidance stress (WAS) and the post-inflammatory (post-TNBS) models, were used to study the impact of proteasome inhibition on the regulation of intestinal permeability. We found that the pharmacological inhibition of the proteasome (with PR-957) or the use of knock-out mice for a subunit of the proteasome (β2i -/-) limit intestinal hyperpermeability occured in IBS-Like models. Moreover, we found that oral supplementation with glutamine also reduces intestinal hyperpermeability, wich, thus, can be considered as a putative nutritional treatment for IBS. A colonic proteomic study of WAS mice and a study of colonic ubiquitoma in IBS patients with diarrheal profiles confirmed the involvement of proteasome in the pathophysiology of IBS. Therefore, the link between obesity and IBS was examined by combining models of obesity (ob/ob genetic and high-fat diet [HFD] models) with WAS model. Only HFD mice displayed enhanced intestinal hyperpermeability and higher plasma corticosterone levels in response to WAS. Further studies suggest that these results, themselve, are independent of leptin, glycaemia and gut microbiota. This study paves new ways of treating patients suffering from IBS, by nutritional intervention via glutamine or by using the proteasome as a therapeutic target. We also suggest a role of diet (high fat) in the development of intestinal functional disorders during obesity.
|
548 |
Mechanismy imunitní dysregulace vedoucí k nespecifickému střevnímu zánětu / Mechanisms of immune dysregulation leading to inflammatory bowel diseaseHoráčková, Klára January 2020 (has links)
Bc. Klára Horáčková DIPLOMA THESIS Mechanisms of immune dysregulation leading to inflammatory bowel disease Abstract Inflammatory bowel disease (IBD) is a complex disorder characterized by chronic inflammation of the gastrointestinal tract. Classical IBD is a multifactorial disease with adulthood or later-childhood onset. However, children with very early onset IBD (VEO-IBD, before 6 years of age) are a specific cohort, whose pathology can be caused by severe genetic defects in genes connected to immune homeostasis in the gut. We aimed to identify the causal genetic variants in 20 pediatric patients diagnosed with IBD (age of onset from 3 to 154 months) using whole exome sequencing (WES). We evaluated several bioinformatical approaches for WES data analysis. This included a comparison of two methods of variant identification using VarScan2 or GATK4-based tools. Furthermore, we compared 4 gene lists ("virtual panels") for variant filtering, one of which was compiled purposefully for this thesis. We identified and validated via segregation analysis 5 causal variants in 4 genes (DUOX2 compound heterozygote, FOXP3, NLRP3 and NOD2) accounting for 20 % of the cohort. NOD2 (p.A755V) variant has already been reported in IBD cases, while DUOX2 (p.R1216W + p.A1131T), FOXP3 (p.H400L) and NLRP3 (p.V200M) were newly...
|
549 |
Vliv cílené nutriční intervence na pooperační výsledky u pacientů po střevních resekcích / Influence of targeted nutritional intervention on postoperative results in patients after intestinal resectionsHlaváčková, Iva January 2020 (has links)
This diploma thesis is focused on patients who are undergoing surgery - intestinal resection. In a surgical patient, malnutrition is a frequent and significant negative factor that affects postoperative morbidity and lethality. Proper nutritional care has an irreplaceable role in the prevention and treatment of malnutrition. Nutritional elements are part of the perioperative care of the modern ERAS concept, which leads to reduction in the frequency of postoperative complications and a shortening of the hospitalization duration. The concept emphasizes early physical rehabilitation and shortening of the fasting period around the time of the operation, which leads to a significant saving of body protein. The theoretical part describes particular diseases that lead to surgical treatment. Special attention is paid to idiopathic intestinal inflammations and colorectal cancer. It also includes current recommendations of professional companies. The primary objective of the practical part is to compare two groups of patients who underwent intestinal resection. To find out whether targeted nutritional intervention (before, during and after surgery) has an impact on postoperative convalescence, the frequency of complications and the overall length of hospitalization. The aim was also to improve the quality of...
|
550 |
The experience of ostomy surgery in young women with inflammatory bowel diseaseClark, Ashley 11 February 2022 (has links)
Background: Inflammatory Bowel Disease (IBD) is a chronic, relapsing, autoimmune disease, affecting one in every 150 Canadians. Failure to induce remission of IBD with pharmacotherapy can necessitate surgical interventions, such as the creation of an ostomy. Ostomy surgery can help manage severe IBD and thus improve quality of life; however, individuals living with IBD report the possibility of ostomy surgery as a top concern, which can lead them to refuse or delay this decision until the disease becomes life threatening.
Research Objective: The aim of this study is to understand what factors influence the decision to have ostomy surgery in young women with IBD, how the perception of the surgery compares to the reality of living with an ostomy, and the role healthcare professionals play in this decision.
Methods: Nine participants who (1) identify as female, (2) are between the ages of 19 and 30, and (3) are currently living with an ostomy to treat IBD were recruited for this study. Additionally, seven healthcare professionals who work with IBD patients were recruited. Participants were invited for an individual, semi-structured interview.
Findings: Young adult women living with an ostomy to treat their IBD reflected on their initial fears and concerns about undergoing surgery. Due to the severity of their illness, the majority of participants had requested surgery after having some time to adjust to the idea. This request, however, was often met with resistance or obstacles in the healthcare system. Healthcare professionals share mixed perceptions of ostomy surgery, with some viewing it as a last resort and others perceiving it as a treatment option. Once surgery had been performed, young adult women describe some challenges adjusting to life with an ostomy; but the majority report experiencing an overall improvement in quality of life.
Conclusion: Understanding the perceptions that influence how young women perceive ostomies prior to versus after surgery will help identify the factors that influence the decision-making process for ostomy surgery, such as gender, age and stigma. Challenging current beliefs and assumptions may allow more supportive conversations between healthcare professionals and patients and provide insight on the actual lived experience of young women living with an ostomy. / Graduate / 2023-01-13
|
Page generated in 0.0306 seconds